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1370Degree of Predicted Minor Histocompatibility Antigen
Mismatch Correlates with Poorer Clinical Outcomes
in Nonmyeloablative Allogeneic Hematopoietic
Cell Transplantation
Malene Erup Larsen,1 Brian Kornblit,2
Mette Voldby Larsen,1 Tania Nicole Masmas,2 Morten Nielsen,1 Martin Thiim,1
Peter Garred,3 Anette Stryhn,4 Ole Lund,1 Soren Buus,4 Lars Vindelov2In fully HLA-matched allogeneic hematopoietic cell transplantation (HCT), the main mechanism of the ben-
eficial graft-versus-tumor (GVT) effect and of detrimental graft-versus-host disease (GVHD) is believed to be
caused by donor cytotoxic T cells directed against disparate recipient minor histocompatibility antigens
(miHAs). The most common origin of disparate miHAs is nonsynonymous single nucleotide polymorphism
(nsSNP) differences between donors and patients. To date, only some 30 miHAs have been identified and
registered, but considering the many different HLA types in the human population, as well as all the possible
nsSNP differences between any 2 individuals, it is likely that many miHAs have yet to be discovered. The
objective of the current study was to predict novel HLA-A– and HLA-B–restricted miHAs in a cohort of
patients treated with nonmyeloablative conditioning allogeneic HCT (matched related donor, n 5 70;
matched unrelated donor, n 5 56) for a hematologic malignancy. Initially, the cohort was genotyped for
53 nsSNPs in 11 knownmiHA source proteins. Twenty-three nsSNPs within 6miHA source proteins showed
variation in the graft-versus-host (GVH) direction. No correlation between the number of disparate nsSNPs
and clinical outcome was seen. Next, miHAs in the GVH direction were predicted for each patient–donor
pair. Using the NetMHCpan predictor, we identified peptides encompassing an nsSNP variant uniquely
expressed by the patient and with predicted binding to any of the HLA-A or -B molecules expressed by
the patient and donor. Patients with more than the median of 3 predicted miHAs had a significantly lower
5-year overall survival (42% vs 70%, P 5 .0060; adjusted hazard ratio [HR], 2.6, P 5 .0047) and significantly
higher treatment-related mortality (39% vs 10%, P5 .0094; adjusted HR, 4.6, P5 .0038). No association be-
tween the number of predicted miHAs and any other clinical outcome parameters was observed. Collec-
tively, our data suggest that the clinical outcome of HCT is affected not by disparate nsSNPs per se, but
rather by the HLA-restricted presentation and recognition of peptides encompassing these. Our data also
suggest that 6 of the 11 proteins included in the current study could contain moremiHAs yet to be identified,
and that the presence of multiple miHAs confers a higher risk of mortality after nonmyeloablative condition-
ing HCT. Furthermore, our data suggest a possible role for in silico basedmiHA predictions in donor selection
as well as in selecting candidate miHAs for further evaluation in in vitro and in vivo experiments.
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In recent years, the role of minor histocompatibility
antigens (miHAs) in HLA-matched allogeneic hemato-
poietic cell transplantation (HCT) has become increas-
ingly evident. miHAs are immunogenic HLA-presented
peptides derived from protein products of polymorphic
genes that are disparate between patient and donor [1].
Although most of these polymorphic proteins result
from nonsynonymous single nucleotide polymorphisms
(nsSNPs) in autosomal genes, miHAs also may be
caused by gene deletions, genetic variation in noncoding
regions affecting gene transcription or the presence of Y
chromosome–encoded proteins in sex-mismatched
HCT [2-5]. Depending on their tissue distribution,
miHAs with broad tissue expression may induce graft-
versus-host-disease (GVHD), whereas miHAs, which
are expressed only in hematopoietic tissue, may induce
a graft-versus-tumor (GVT) effect [1]. Several studies
have linked the presence of miHA-specific T cells
posttransplantation with graft rejection [6,7], GVHD
[8-10], and the GVT effect [11-13]. Because GHVD is
a major cause of transplantation-related morbidity and
treatment-related mortality (TRM) [14], identification
and characterization of miHAs specifically expressed
in hematopoietic but not other normal tissues could
contribute to the development of selective GVT-
oriented immunotherapy by separating the beneficial
GVT effect from GVHD. Approximately 30 miHAs
have been identified [15] by various methods, including
peptide elution from the major histocompatibility com-
plex (MHC) [12,16], expressional cloning [3,17,18],
genetic linkage analysis [11,19], and genome-wide asso-
ciation analysis [20-22]. Common to all these methods is
that they identify only a few miHAs restricted to no
more than few HLA types. Considering the diversity
of the HLA system with .3500 known alleles [23-25],
as well as the .120,000 known allelic nsSNP variants
[26], it seems likely that many miHAs have yet to be
identified. If GVT-oriented immunotherapy is to be
broadly applicable to a large number of patients, then
the number of known miHAs needs to be expanded in
a systematic manner and on a larger scale using
computerized methods [27]. This has been addressed
by several different bioinformatics techniques using
algorithms to integrate databases containing informa-
tion about protein processing, MHC–peptide binding,
SNP data, and tissue-specific gene expression [11,28-
30]. NetMHCpan [31] is an MHC–peptide binding
prediction tool capable of predicting the binding of
peptides to any MHC molecule with a known protein
sequence. The method is based on an Artificial Neural
Network trained on experimental MHC–peptide
binding data. In 2 recent comparisons, NetMHCpan
has proven superior to other available predictors in
predicting HLA class I binding [32,33]. The purpose
of the current project was to investigate theassociation between the number of predicted
miHAs and the outcome after allogeneic HCT with
nonmyeloablative (NMA) conditioning. Based on
patient and donor HLA-A and -B types and genotype
for a number of nsSNPs, miHAs were predicted in
proteins already known to contain miHAs. Known
miHA source proteins were chosen because the previous
discovery of miHAs in these proteins indicates that they
are expressed in relevant tissues and have an expression
and degradation frequency that allows peptides from the
proteins to be presented by HLA molecules.MATERIALS AND METHODS
Patients
This analysis includes data from 126 consecutive pa-
tients who underwent allogeneic HCT with a peripheral
blood graft from an HLA-identical related or 10/10
allele-matched unrelated donor after NMA condition-
ing between April 2000 and July 2007 at the allo-
HCT unit, Department of Hematology, Rigshospitalet,
Copenhagen. For related donors, donor selection was
based on serologic typing for HLA-A, -B, and -C, and
on molecular typing for HLA class II. For unrelated
donors, donor selection was based on molecular typing
for HLA-A, -B, -C, -DRB1, and -DQB1. When avail-
able, HLA-identical siblings were preferred to matched
unrelated donors, and cytomegalovirus serostatus and
sex mismatch were taken into account when possible.
Molecular class I typing of related patients and donors
was performed retrospectively as part of this study. All
patients were treated for a malignant hematologic
disease, including acute myelogenous leukemia/myelo-
dysplastic syndrome (n5 58), non-Hodgkin lymphoma
(n 5 25) (follicular lymphoma, n 5 15; diffuse large B
cell lymphoma, n5 4; mantle cell lymphoma, n5 3; pe-
ripheral T cell lymphoma, n5 3), chronic lymphocytic
leukemia (n 5 18), multiple myeloma (n 5 12), and
Hodgkin disease (n 5 13). The diseases were classified
as low, standard, or high risk according to Kahl et al.
[34]. Detailed patient and donor demographic data are
summarized in Table 1. Donor treatment, conditioning
regimen, and supportive care were as described previ-
ously [35]. All patients were conditioned with fludara-
bine 30 mg/m2 for 3 days and 2 Gy of total body
irradiation (TBI), except for 2 patients who were condi-
tioned with 2 Gy TBI only. Acute and chronic GVHD
(aGVHD, cGVHD) was diagnosed according to
standard criteria [36]. Informed consent was obtained
from all patients, and the local Ethics Committee
approved the study design.
Prediction of miHAs
Eleven non–Y chromosomal proteins (Table 2)
known to contain miHAs were selected from the
dbMinor database [15]. The amino acid sequences of
Table 1. Patient and Donor Characteristics
Variable Patients (n 5 126), n (%)
Patient age, years
Median553
Range 19–69
Donor age, years
Median544
Range 19–68
Patient age # 40 years 18 (14%)
Patient age > 40 years 108 (86%)
Donor age # 40 years 50 (40%)
Donor age > 40 years 76 (60%)
Type of donor
Matched related 70 (56%)
Matched unrelated 56 (44%)
Sex of patient/donor
Male/female 28 (22%)
Other combinations 98 (78%)
Underlying disease*
Low risk 25 (20%)
Standard risk 63 (50%)
High risk 38 (30%)
CMV status of patient/donor
CMV-negative/CMV-negative 25 (20%)
Other combinations 101 (80%)
CMV indicates cytomegalovirus.
*Underlying disease was classified as low, standard, or high risk accord-
ing to Kahl et al. [34].
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the nsSNPs in these were identified using dbSNP
[38]. NetMHCpan was used to predict the binding to
the HLA-A or -B molecules presented by the patients
for all peptides with a length of 8-11 amino acids en-
compassing the nsSNPs. For each HLA allele, binding
peptides were defined as those peptides with a pre-
dicted binding strength within the top 1% among ran-
dom natural peptides. A total of 53 nsSNPs were
selected for genotyping (Table 3), all with a minor al-
lele frequency of $1% in the HapMap CEU popula-
tion [39] and located within peptides predicted to
bind to at least one of the HLA-A or -B molecules rep-
resented in the patient cohort. For a peptide to be con-
sidered a potential miHA in the graft-versus-host
(GVH) direction for a given patient, the peptide
should be predicted to bind at least one of the patient’s
HLA-A or -B molecules according to the foregoing
definition, and the patient should carry the alleleTable 2. Proteins Selected from dbMinor and Their Reported miH
Protein Symbol Protein Name Protein L
HMHA1 Histocompatibility (minor) HA-1 11
MYO1G Myosin 1G 10
AKAP13 A kinase (PRKA) anchor protein 13 28
KIAA0020 KIAA0020 6
HMHB1 Histocompatibility (minor) HB1
BCL2A1 BCL2-related protein A1 1
LRH1 Purinergic receptor P2X5 isoform A 4
ECGF1 Endothelial cell growth factor 4
CTSH Cathepsin H 3
TOR3A Torsin family 3, member A 3
SP110 SP110 nuclear body protein, isoform A 6
miHAs indicates minor histocompatibility antigen.coding the binding peptide variant, whereas the donor
should be homozygous for the alternative allele. This
definition also allows for the donor’s variant of the
peptide to be a predicted binder, because the donor’s
T cells might recognize the difference between the 2
variant peptides.Genotyping
Pretransplantation DNA from patients and DNA
from donors were genotyped for the 53 nsSNPs using
a 12-plex format GenomeLab SNPstream genotyping
system (Beckman Coulter, Brea, CA) according to the
manufacturer’s protocol. The genotype of each of the
polymorphisms was validated in 5-10 samples by direct
Sanger sequencing (ABI Prism 3100 Genetic Analyzer;
Applied Biosystems, Foster City, CA) using PCR
primers designed for the SNPstream Genotyping
system (autoprimer.com; Beckman Coulter) and
purification by ethanol precipitation as described pre-
viously [40]. In some cases, failed or missing genotypes
could be inferred from linkage disequilibrium (LD)
with the successfully genotyped nsSNPs. The criterion
for inferring genotypes in this way was complete LD
(R25 1) using the CEU population in the HapMap da-
tabase [39]. To validate the genotyping assay in the
event of departure from the Hardy-Weinberg equilib-
rium (HWE), a control population of 96 healthy
Danish Caucasian blood donors was genotyped by
direct sequencing for the relevant nsSNPs.Statistical Analysis
LD, expressed as the squared correlation coeffi-
cient, R2, quantified between all pairs of biallelic loci
was estimated using SNPAlyze version 4.0 (Dynacom,
Yokohama, Japan). The HWE was assessed separately
in the patient and donor populations, and analyzed us-
ing gene frequencies obtained by simple gene counting
and the c2 test. Where applicable, Fisher’s exact test
was used to compare frequencies.
Cox regression was used to estimate the association
between the number of nsSNP differences or predicted
miHAs and overall survival (OS), progression-freeAs
ength, aa Known miHA Sequence
38 HA1, HA-1/B60 VLHDDLLEA, KECVLHDDL
18 HA-2 YIGEVLVSV
17 HA-3 VTEPGTAQY
49 HA-8 RTLDKVLEV
41 HB-1H, HB-1Y EEKRGSLHVW, EEKRGSLYW
75 ACC-1, ACC-2 DYLQYVLQI, KEFEDDIINW
22 LRH-1 TPNQRQNVC
82 LB-ECGF-1H RPHAIRRPLAL
35 CTSH/A31, A33 ATLPLLCAR, WATLPLLCAR
97 LB-ADIR-1F SVAPALALFPA
89 SP110(HwA-9) SLPRGTSTPK
Table 3. Overview of the Selected nsSNP with Variation in the GVH Direction, Predicted miHAs, and Prevalence in Patients
Protein nsSNPs
Predicted
miHAs around
nsSNP
Patients with
nsSNP in GVH
Direction
Patients with
Predicted
miHA(s) HLA Types Covered
Example Predicted
miHA
Known miHAs
around nsSNP
SP110 rs9061 6 15 11* A0301, A1101, A6801, B3801, B4001 KLTSKMNA(K/E)
rs28930679 2 28 11* B4001 (A/V)EEDSEEMPSL
rs1135791 12 47 31 A0301, A1101, A3101, A3102, A3103, B0801, B2702, B4001 (M/T)TLGELLK
rs3948463 11 12 12 11 HLA-As, B3505, B1302, B5101, B5201 MLWSCTFCR(I/M)
rs3948464 17 25 2 A3001, A3101, B2702, B2705 RTKCARKSR(L/S)K
HMHB1 rs161557 14 25 15 A3001, A0201, A0203, A2402, 8 HLA-Bs (Y/H)VWKSELVEV HB-1H, HB-1Y
AKAP13 rs745191 4 24 16 A0101, 11 HLA-Bs PSDLALL(V/G)
rs2061821 8 33 26 A0101, A2902, A3002, A8001, A2501, A2601,11 HLA-Bs V(M/T)EPGTAQY HA-3
rs2061822 8 35 21 A0301, A1101, 10 HLA-Bs LMNPDATV(W/R)K
rs2061824 2 34 6 A3001, B4001 (R/C)EESADAPV
rs4075254 7 35 19 A0101, A1101, A0301, 7 HLA-Bs NTDSSLQS(V/M)
rs4075256 6 35 24 B0702, B5501, B5601, B1401, B1402, B3901, B3701, B4001 RPLEDRA(V/A)GL
rs4843074 2 33 0 A0203, B3502, B3503 DALNCSQ(P/A)SPL
rs4843075 8 36 2 A6802, B4001, B4901, B1302, B3701, B4501, B5001 CEVSG(D/N)VTV
rs7162168 8 36 16 A0301, A3101, A3102, A3103, A6601, A6801, 7 HLA-Bs V(M/T)RAPPSGR
rs7177107 4 15 4 A6801, A0301, B4501 KLCDNIVS(K/E)
rs34434221 4 5 0 A1101, B0702, B5501, B5601, B3801, B5101 (Q/K)PVDKISV
rs35624420 5 2 0 7 HLA-As, 7 HLA-Bs RAVGLSTS(F/S)
BCL2A1 rs1138357 16 29 25 10 HLA-As, 9 HLA-Bs YLQ(Y/C)VLQI ACC-1
rs1138358 17 29 24 8 HLA-As, 7 HLA-Bs VLQ(K/N)VAFSV
rs3826007 14 27 16 A3201, A2501, 14 HLA-Bs KEFEDDII(G/D)II ACC-2
MYO1G rs3735485 10 27 12 8 HLA-As, B1518, B0801, B0809 D(M/T)HHRHHL
rs7792760 9 26 8 A0301, A3001, A3101, A3102, A3103, A6801, B3901 RLKTL(Q/R)DK
KIAA0020 rs2173904 7 33 19* A0301, A1101, A3001, A2301, A2402, 9 HLA-Bs KSADH(R/P)TLDK HA-8
rs2270891 11 6 19* A0201, A0301, A1101, A3001, A3201, 10 HLA-Bs LE(V/L)QPEKL
rs10968457 3 6 2 A0301, A3001 KQFTGK(S/N)TK
miHA indicates minor histocompatibility antigen, nsSNP, nonsynonymous single nucleotide polymorphism.
For each nsSNP, the following are listed: number of predictedmiHAs, number of patients with the nsSNP difference in theGVHdirection, the number of patients with at least one predictedmiHA around the nsSNP, the
HLA types to which the miHAs around the nsSNP are predicted to bind, an example miHA, and the name of any known miHAs around the nsSNP.
*Number of patients with predicted miHAs containing either of 2 close SNPs.
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1374 Biol Blood Marrow Transplant 16:1370-1381, 2010M. E. Larsen et al.survival (PFS), relapse incidence (RI), relapse-related
mortality (RRM), TRM, grade II-IV aGVHD, grade
III-IV aGVHD, or extensive cGVHD. Probability of
OS and PFS was estimated by the Kaplan-Meier
method, and comparisons were made with the log-
rank test, whereas the cumulative incidences of RI,
RRM, TRM, and GVHD were compared using Gray’s
K test [41,42]. In the estimates of RI, RRM, TRM, and
GVHD, death before relapse, death with or without
relapse, death without GVHD, and retransplantation
were handled as competing events when appropriate
[42]. OS was measured from the time of transplantation
until death from any cause. Patients still alive at the
time of analysis were censored at the date of last
follow-up. PFS was calculated from the date of trans-
plantation to the date of first relapse or death. Patients
who were alive and in remission were censored at date
of last follow-up. TRM was defined as death in com-
plete remission (CR) or death where it was not possible
to assess disease status before death. RRM was defined
as death during relapsed or progressive disease. In the
multivariate Cox regression models, all of the covari-
ates listed in Table 1, along with the presence of
GVHD (time-dependent covariate), were entered one
by one into a pairwise model together with the number
of nsSNP differences or predicted miHAs. The covari-
ates were kept in the final model if they remained signif-
icant (P \ .05) or altered the association with the
number of nsSNP differences or predicted miHAs by
.10%. All P values were 2-tailed, and P \.05 was
considered significant.RESULTS
Transplantation Outcome
In our cohort of 126 patients, the median follow-
up was 837 days (range, 30-3178 days). The 5-year
OS and PFS were 58% and 49%, respectively. The
probability of grade II-IV aGVHD within the first
year was 69%, and the 3-year probability of extensive
cGVHD was 44%.Genotyping of Patients
The patient and donor cohorts were successfully
genotyped for 31 of the 53 selected nsSNPs, and a var-
iation in the GVH direction was observed in 23 of
these. There was no significant difference in the dis-
tribution of genotype frequencies between patients
and donors, except for rs2061821 (P 5 .036) and
rs1135791 (P5 .046) (Table 4). Sixteen of 23 nsSNPs
adhered to the HWE (P ..05). Of the 7 polymor-
phisms that departed from the HWE, 6 were in strong
LD located in AKAP13 (Table 5), and 1 was located in
SP110 (rs9061). Genotypes of SNPs that failed the
HWE assumption were validated by direct sequencingof approximately 10% of the patient and donor co-
horts. Furthermore, to ensure unbiased genotyping,
the assay for these 7 nsSNPs was further validated in
a cohort of 96 healthy controls (data not shown).
When genotypes in the 96 control individuals were
analyzed together with donor samples, all 7 nsSNPs
adhered to HWE (data not shown). Three of the
nsSNPs (rs4843075, rs7162168, and rs10968457)
that failed genotyping were inferred based on com-
plete LD (R2 5 1) according to the HapMap CEU
population to some of the 23 varying nsSNPs, thus
resulting in a total of 26 varying nsSNPs. In detail,
rs4843075 and rs7162168 in the AKAP13 protein
were in LD with a block of 5 nsSNPs (rs4843074,
rs2061821, rs2061824, rs4075256, and rs4075254),
which were successfully genotyped. In the KIA0020
protein, rs10968457 was in LD with rs2270891.Effect of Number of nsSNPs in the GVH
Direction on Outcome
The median number of nsSNP differences in the
GVH direction between patient and donor was 4
(range, 0-17). Patients with #4 nsSNP differences in
the GVH direction had a nonsignificant higher
5-year OS and PFS than patients with .4 nsSNP dif-
ferences (Table 6 and Figure 1A). Likewise, patients
with#4 nsSNP differences had a nonsignificant lower
5-year TRM than patients with.4 nsSNP differences
(Figure 1B). No difference in outcome was observed
for any of the other clinical parameters (P ..30).Identification of Potential miHAs
A total of 26 nsSNPs within 6 of the 11 proteins
showed variation in the GVH direction (Table 3).
Whenever a patient–donor pair had an nsSNP differ-
ence in the GVH direction, the binding of peptides
containing the nsSNP to the patient’s HLA-A and -B
molecules was assessed using NetMHCpan [31]. A
binding strength threshold of 1% (binding strength
falling within the top 1% compared with a large set
of random natural peptides) was used in the analyses.
Thresholds of 0.5% and 2% were tested without sig-
nificantly altering the outcome of the analyses. In
some cases, more than one peptide of length 8-11 aa
was a predicted binder, and thus each nsSNP in the
GVH direction could result in 1, 2, or more potential
miHAs for a given patient. Significantly fewer nsSNP
differences were present between patients and donors
when the donor was matched related compared with
matched unrelated (2 vs 7; P\1025; Mann-Whitney
U test). Similarly, related patient–donor pairs had
fewer predicted miHAs than unrelated pairs (1 vs 5;
P \1023; Mann-Whitney U test). Figure 2A shows
the distribution of patient–donor pairs according to
number of nsSNP differences in the GVH direction,
Table 4. Distribution of Genotypes
nsSNP
Major
allele A
Minor
allele a
Fisher’s
exact test
Patients Donors
Failed
Genotypes, % HWE AA, % Aa, % aa, %
Failed
Genotypes, % HWE AA, % Aa, % aa, %
rs9061 G A 0.45 0 0.80 81.7 16.7 1.6 0.8 0.01 84.8 12.0 3.2
rs28930679 C T 0.27 2.4 0.86 60.2 35.0 4.8 1.6 0.15 55.6 33.9 10.5
rs1135791 T C 0.05 4.0 0.08 23.1 58.7 18.2 4.0 0.33 30.6 44.6 24.8
rs3948463 G A 1.00 3.2 0.64 83.6 15.6 0.8 3.2 0.59 82.8 16.4 0.8
rs3948464 C T 0.38 0.8 0.46 71.2 24.8 4.0 0 0.19 78.6 18.2 3.2
rs161557 C T 0.75 2.4 0.83 57.7 36.6 5.7 3.2 0.42 59.8 32.8 7.4
rs745191 G T 0.22 1.6 0.12 53.2 43.6 3.2 3.2 0.32 45.1 47.5 7.4
rs2061821 C T 0.04 4.8 0.01 28.3 60.8 10.9 4.8 0.003 40.8 55.0 4.2
rs2061822 C T 0.25 0.8 0.01 32.8 59.2 8 1.6 0.02 41.9 53.2 4.8
rs2061824 T C 0.08 1.6 0.002 27.4 62.9 9.7 4.0 0.01 39.7 55.4 4.9
rs4075254 A G 0.06 3.2 0.01 27.9 61.5 10.6 4.8 0.01 40.0 55.0 5.0
rs4075256 C T 0.16 2.4 0.005 27.6 61.8 10.6 2.4 0.02 38.2 55.3 6.5
rs4843074 G C 0.11 7.1 0.001 25.6 64.1 10.3 5.6 0.02 37.8 55.5 6.7
rs7177107 G A 0.15 5.6 0.23 67.2 26.9 5.9 5.6 0.34 64.7 33.6 1.7
rs34434221 A C 0.27 10.3 0.81 95.6 4.4 0 4.0 0.89 98.3 1.7 0
rs35624420 C T 1.00 0 0.93 98.4 1.6 0 0 0.93 97.6 2.4 0
rs1138357 G A 0.94 3.2 0.52 56.6 35.2 8.2 2.4 0.56 58.5 34.1 7.4
rs1138358 T G 1.00 0.8 0.46 57.6 34.4 8.0 0.8 0.61 58.4 34.4 7.2
rs3826007 G A 0.64 7.1 0.38 57.3 34.2 8.5 4.8 0.73 61.7 32.5 5.8
rs3735485 C T 0.74 3.2 0.99 73.8 23.8 2.4 3.2 0.27 77.0 19.7 3.3
rs7792760 G A 1.00 0 0.20 74.6 21.4 4.0 0.8 0.44 75.2 21.6 3.2
rs2173904 G C 0.60 2.4 0.65 33.3 46.4 20.3 7.1 0.72 28.0 47.5 24.5
rs2270891 G T 1.00 1.6 0.49 92.7 6.5 0.8 2.4 0.49 92.7 6.5 0.8
Observed frequencies of genotypes in patients and donors separately. The minor alleles were defined as the alleles with the lowest frequency, whereas
themajor alleles were defined as the alleles with the highest frequency. Differences in genotype distribution between patients and donors for each nsSNP
were assessed by Fisher’s exact test. P values <.05 are in bold type.
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predicted miHAs in the GVH direction.Effect of Number of Predicted miHAs in the
GVH Direction on Outcome
There was a median of 3 predicted miHAs per
patient–donor pair (range, 0-16). A total of 215 miHAs
were predicted for the HLA types and nsSNP differ-
ences represented in our cohort (Table 3), and 172 of
these matched at least one patient. Patients with .3
predicted mismatched miHAs in the GVH direction
had a significantly lower probability of 5-year OS
and PFS and a higher probability of 5-year TRM com-
pared with patients with#3 predicted miHAs (Table 6
and Figure 3A and B). The presence of .3 predicted
miHAs also was a significant risk factor associated
with 5-year OS, PFS, and TRM in both the unadjusted
and adjusted Cox regression models (Table 6 and
Table 7). No association between the number of
miHAs and any other clinical outcome parameterTable 5. Pairwise LinkageDisequilibrium, Expressed asR2 between
Populations
Patient/Donor Rs2061821 Rs2061822
Rs2061822 0.85 / 0.97
Rs2061824 1/1 0.86 /1
Rs4075254 1/1 0.86 /1
Rs4075256 1/1 0.86 /1
Rs4843074 1/1 0.85 /1was observed. Other cutoffs besides the median of 3
predicted miHAs were tested as well. The difference
in OS and PFS was significant for all cutoffs between
0 and 6 predicted miHAs (data not shown). The
same was true for TRM, with the exception of a cutoff
of 1 predicted miHA (P 5 .07) (data not shown). The
probability of 5-year OS showed a successive decrease
with 0, 1-2, and .2 predicted miHAs per patient
(hazard ratio [HR], 2.4; 95% confidence interval
[CI], 1.5-4.0; P5 .0005), implying a miHA dosage ef-
fect (Figure 4). Patients with any predicted miHAs had
a significantly lower 5-year OS (46% vs 93%; HR, 8.1;
95% CI, 1.9-34; P5 .60 1023) than patients with 0 pre-
dicted miHAs. Apart from the association between the
number of predicted miHAs in a patient–donor pair
and outcome, some protein-, nsSNP-, and predicted
minor-specific associations with OS, PFS, or TRM
were observed. The presence of any miHAs in SP110
and AKAP13 (Table 8), patient homozygosity for the
minor allele of 3 nsSNPs in tight LD in AKAP13
(rs2061821, rs2061822, rs4075254) (Table 5 and 8),AKAP13Polymorphisms out ofHWE, in the Patient andDonor
Rs2061824 Rs4075254 Rs4075256
1/1
1/1 1/1
1/1 1/1 1/1
Table 6. Univariate Analyses of the Effect of Number of PredictedmiHAs on Different Clinical Outcome Parameters after 5 Years
Parameter
nsSNP Differences
# 4 vs > 4* HR (95% CI) P
Predicted miHAs
#3 vs >3† HR (95%CI) P
OS 66.3 % vs 48.9 % 1.7 (0.9–3.1) .09 70.1 % vs 42.2 % 2.3 (1.2–4.2) .0060
PFS 54.5 % vs 43.2 % 1.5 (0.9–2.6) .13 58.3 % vs 36.7 % 2.0 (1.2–3.5) .0082
TRM 12.3 % vs 34.0 % 2.2 (0.9–5.5) .09 9.9 % vs 39.2 % 3.4 (1.3–8.9) .0094
RRM 24.4 % vs 25.9 % 1.3 (0.6–3.0) .63 22.2 % vs 30.7 % 1.7 (0.7–3.8) .39
RI 37.3 % vs 30.6 % 1.2 (0.6–2.3) .76 34.8 % vs 34.6 % 1.5 (0.8–2.9) .45
Acute GVHD grade II-IV 72.7 % vs 75.7 % 1.0 (0.7–1.5) .75 71.8 % vs 76.9 % 1.1 (0.7–1.7) .95
Acute GVHD grade III-IV 21.2 % vs 20.1 % 1.0 (0.4–2.1) .82 19.6 % vs 22.0 % 1.2 (0.5–2.5) .82
Extensive chronic GVHD 62.3 % vs 63.7 % 0.9 (0.5–1.6) .41 62.2 % vs 63.8 % 1.0 (0.6–1.7) .36
HR, hazard ratio; CI, confidence interval; P values <.05 are in bold type.
*Patient–donor pairs are divided into those with #4 or >4 nsSNP differences in the GVH direction.
†Patient–donor pairs are divided into those with #3 or >3 predicted miHAs.
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with outcome (Table 8). The multiple comparison
penalty paid in these analyses increases the
Bonferroni-corrected P values to well above the .05
threshold. According to dbMinor [15], proteins
AKAP13 and KIAA0020 are classified as broadly ex-
pressed, whereas SP110, HMHB1, BCL2A1, and
MYO1G are classified as hematopoietically expressed.
No tissue-specific effect was observed when dividing
patients into those with predicted miHAs only from
hematopoietically expressed proteins, only from
broadly expressed proteins, or from both kinds of pro-
teins (5-year OS, 47% vs 49% vs 41%; P 5 .95).DISCUSSION
To the best of our knowledge, the present study is
the first to investigate the association between the num-
ber of predicted miHAs in known miHA source proteins
and clinical outcome after matched allogeneic HCT
with NMA conditioning. By identifying nsSNP differ-
ences and using an Artificial Neural Network tool
(NetMHCpan) 172 patient–donor specific miHAs wereFigure 1. Probability ofOS (A) and cumulative incidence of TRM (B) stratified apredicted. Compared with the known HLA-A and -B
binding miHAs (n5 19; source dbMinor [15]), this rep-
resents an almost 10-fold increase, suggesting that the
investigated miHA source proteins contain additional
miHAs that have yet to be identified. Among the pre-
dicted miHAs, 6 were already in the dbMinor database
[15]: HA-3 (VTEPGTAQY), HA-8 (RTLDKVLEV),
HB-1H (EEKRGSLHVW), HB-1Y (EEKRGSLY
VW), ACC-1 (DYLQYVLQI), and ACC2 (KEFED-
DIINW). The dbMinor database currently contains
29 miHAs, of which 10 originate from the Y chromo-
some and thus were not considered in this study. We
predicted only 6 of the remaining 19 previously identi-
fied HLA-A and -B binding miHAs, because the
corresponding nsSNP failed genotyping (6 miHAs),
the rs number was not listed in dbSNP (2 miHAs), or
the miHA was not caused by an nsSNP (5 miHAs).
In line with the greater degree of genetic variation
between unrelated individuals, significantly fewer
nsSNP differences and predicted miHAs in the GVH
direction were observed with sibling patient–donor
pairs compared with matched unrelated pairs. The pa-
tient–donor relationship did not significantly influence
the transplantation outcome, however. Whenccording to themedian number of nsSNP differences in the GVH direction.
Figure 2. Histograms showing the distribution of patients by number of observed nsSNP differences in the GVH direction (A) and by number of
predicted miHAs in the GVH direction (B). MUD, matched unrelated donor; MRD, matched related donor.
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GVH direction, it was possible to observe only a trend
toward superior transplantation outcomes in patients
with few nsSNP differences. But, when HLA restric-
tions were also taken into account by using miHA pre-
dictions, we were able to show that the presence of the
median of#3 miHA disparities within a patient–donor
pair, was a significant independent factor associated
with a higher probability of both OS and PFS and
lower risk of TRM. Although the group of patients
with 0 predicted miHAs had the highest OS compared
with all other patients, the median was chosen to
provide an unbiased level for dichotomization in the
analyses, because the very few (2) events in the group
of patients with 0 predicted miHAs could affect theFigure 3. Probability of OS (A) and cumulative incidence of TRM (B) strati
direction within a patient–donor pair.reliability of the statistical comparison when using
0 predicted miHAs as the level of dichotomization.
These data suggest that the outcome of HCT
depends on matching donor and recipient for HLA-
restricted miHAs, rather than on the mere matching
of nsSNPs. No association between the number of
predicted miHAs and aGVHD or cGVHD was ob-
served. Although GVHD is considered one of the
main causes of TRM [14], TRM also encompasses
patients who succumbed to infection. Because it is un-
likely that the number of predicted miHAs is associ-
ated with the risk of infection without affecting the
incidence of GVHD, the discrepancy between TRM
and GVHD most likely results from insufficient study
power. Given that no associations with relapse-relatedfied according to the median number of predicted miHAs in the GVH
Table 7. Multivariate Cox Regression Analysis of the Association of Number of Predicted miHAs with 5-Year Transplantation
Outcome
Outcome Covariate HR 95% CI P
OS Number of predicted miHAs #3 Ref.
>3 2.2 1.2–4.0 .014
Acute GVHD grade III-IV Absence Ref.
Presence 3.2 1.7–5.9 <.001
Extensive chronic GVHD Absence Ref.
Presence 0.8 0.35–2.0 .67
PFS Number of predicted miHAs #3 Ref.
>3 2.0 1.1–3.4 .014
Acute GVHD grade III-IV Absence Ref.
Presence 2.7 1.5–4.8 .001
Extensive chronic GVHD Absence Ref.
Presence 1.3 0.60–2.7 .525
TRM Number of predicted miHAs #3 Ref.
>3 4.5 1.7–12.3 .003
Patient age #40 years Ref.
>40 years 3.8 0.5–29 .198
Donor age #40 years Ref.
>40 years 2.2 0.8–5.9 .126
Acute GVHD grade III-IV Absence Ref.
Presence 4.4 1.9–10.6 .001
Extensive chronic GVHD Absence Ref.
Presence 1.3 0.4–4.9 .669
OS indicates overall survival; PFS, progression-free survival; TRM, treatment-related mortality; GVHD, graft-versus-host disease; miHA, minor
histocompatibility antigen.
Covariates were included in the final models only if they changed the estimate of the main variable by at least 10% or were significantly associated with
outcome in pairwise analyses. P values <.05 are in bold type.
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that the presence of many miHAs confers an increased
risk of death rather than inducing the beneficial GVT
effect, implying that mismatching for most miHAs
results in decreased survival.
If the extent of interindividual genetic variation
and HLA diversity is taken into account, then the
current study assesses only a very limited subset of all
possible predicted miHAs. Because many of the
predicted miHAs likely will not initiate cytotoxic T
cell responses because of immunodominance issues
[43], it is of interest that the limited subset of miHAsFigure 4. Probability of OS stratified according to number (0, 1-2, or
.2) of predicted miHAs in the GVH direction.predicted in our study was associated with transplanta-
tion outcome. This could be explained by the assessed
proteins being the source of most relevant miHAs for
transplantation (which we consider unlikely), or by
the degree of miHA disparity in these proteins being
a surrogate marker for the total genome-wide and
HLA-wide miHA disparity within each patient–donor
pair. If the degree of miHA disparity in our study only
represents a proxy for the real patient–donor discrep-
ancy, the exact level of dichotomization also becomes
less important compared with making a distinction
between few or many disparities. Apart from the
impact of the predicted miHAs on transplantation out-
come, the possibility that factors such as the functional
aspects of the nsSNPs cannot be excluded, and the
general heterogeneity of the patient cohort also could
influence the outcome in our cohort.
In several studies of single or very few patients, the
identification and presence of miHA-specific T cells has
been associated with remissions of chronic myeloge-
nous leukemia [11,44] or rejection [7]. However, larger
studies of single or multiple miHA mismatches
restricted to one or few HLA types in patients undergo-
ing allogeneic HCT with sibling donors have uniformly
been associated with GVHD without any association
with RRM [8-10,45-47]. In line with our study, this
suggests that in general, miHA mismatch is not
beneficial. In contrast, no association between miHA
disparity and outcome was observed in a single study
of 730 unrelated HLA-matched allogeneic HCTs
[48], possibly illustrating the impact of increased non-
HLA genetic variation confounding the observations.
Table 8. Single Predicted miHAs, Predicted miHAs around a Single nsSNP, and Predicted miHAs from a Single Protein with
a Significant Impact on OS, PFS, or TRM
Protein nsSNP Difference Predicted miHA Relevant Patients P (OS) P (PFS) P (TRM)
SP110 45 .025 .058 .28
BCL2A1 29 .16 .11 .063
rs1138357 25 .28 .30 .27
YLQYVLQI* 13 .40 .90 .025
RLAQDYLQYV 13 .40 .90 .025
rs1138358 24 .17 .088 .013
VLQKVAFSV 14 .51 .69 .040
AKAP13 49 .041 .062 .37
rs2061821 26 .082 .047 .14
LVMEPGTAQY† 13 .0062 .0022 .0040
rs2061822 21 .41 .29 .03
rs4075254 19 .20 .20 .011
OS indicates overall survival; PFS, progression-free survival; TRM, treatment-related mortality; GVHD, graft-versus-host disease; nsSNP, nonsynony-
mous single nucleotide polymorphism; miHA, minor histocompatibility antigen.
nsSNPs are listed under the protein in which they occur, and predictedmiHAs are listed under the nsSNP that causes themiHA. Bold type denotes P <.05
(not corrected for multiple testing).
*Similar to the known miHA ACC-1:DYLQYVLQI.
†Similar to the known miHA HA-3:VTEPGTAY.
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stricted tissue expression encompassing tissues of hema-
topoietic origin and a broad tissue expression including
nonhematopoietic tissues such as skin, gut, and liver
[49]. It has been suggested that miHAs with a restricted
tissue expression would result in GVT effects without
deleterious GVHD, because the GVHD elicited by
such miHAs would only result in the removal of normal
recipient hematopoiesis. In contrast, miHAs with
a broad tissue expression would carry the risk of induc-
ing potentially life-threatening GVHD. Among the 6
miHA source proteins showing nsSNP variation in
the GVH direction, only AKAP13 and KIAA0020
(accounting for a total of 87 predicted miHAs in our
cohort) are classified as broadly expressed (source:
dbMinor [15]). The other 4 proteins—SP110,
HMHB1,BCL2A1, andMYO1G, accounting for a total
of 128 predicted miHAs—have restricted tissue expres-
sion. However, a comparison of HCT outcome in
patients with predicted miHAs from broadly expressed
proteins, proteins restricted to hematopoietic tissue,
or both types of proteins showed no significant differ-
ences between the 3 patient groups, challenging either
the experimental results on which the classification is
based or the theoretical framework for separating
GVHD and GVT effects [49]. Alternatively, in addition
to creating miHAs, the functional aspects of the nsSNPs
also could decisively influence hematopoiesis and thus
transplantation outcome. Therefore, it is possible that
the current classification of miHAs is simplistic and
will require revision as our understanding grows.
Several limitations apply to the current study.
Predictions were limited to HLA-A and -B molecules,
because NetMHCpan is most accurate for these [50].
miHA predictions were planned for peptides surround-
ing 53 nsSNPs in 11 different non–Y chromosomalproteins. However, technical limitations because of
both the genetic sequence surrounding the nsSNPs
and the nature of the SNPstream genotyping platform
limited the number of successfully genotyped nsSNPs
to 31. Because the 53 nsSNPs at best only are surrogate
markers for the common genetic variation between
individuals, and because the 53 planned and 31 success-
fully genotyped nsSNPs probably represent similar
fractions of the numerous potential nsSNPs in the
entire genome, no further effort was made to pursue
the genotype of the failed 22 nsSNPs. Although most
genotypes adhered to HWE, 7 nsSNPs (6 of which
were in strong LD) departed significantly. These
observations are likely because of small sample size,
because genotypes were confirmed by extensive rese-
quencing, and because adherence to HWE was ob-
served when a control population of 96 healthy blood
donors was included. Furthermore, the significantly
different distribution of rs2061821 and rs1135791
genotypes between patients and donors also was
considered an artifact ascribed to the small study
population, rather than a true association with disease
susceptibility.
In conclusion, the current study presents a feasible
method for large-scale in silico prediction of novel
HLA-A– and -B–restricted miHAs incorporating any
patient–donor HLA types. Although the functional as-
pects of the predicted miHAs are unknown and the
study is purely descriptive, our findings suggest that
the level of predicted miHA discrepancy between
patient and donor could be associated with transplan-
tation outcome. If these observations were to be vali-
dated in independent cohorts, miHA predictions
specific for each patient–donor pair could have a place
in future risk stratification and possibly in guiding
donor selection and therapy. With the current
1380 Biol Blood Marrow Transplant 16:1370-1381, 2010M. E. Larsen et al.advancements in microarray-based genotyping, whole
genome sequencing, and in silico modeling, a genome-
wide and HLA-wide approach is within reach. miHA
predictions could be expanded from encompassing
only a few nsSNPs to all known nonsynonymous ge-
netic variations and both class I and II HLA molecules,
providing a unique miHA map of each patient–donor
pair. This likely would enhance the prognostic value
of the method in selecting the most optimal donor in
those cases for which more than one 10/10 allele-
matched donor was found using the current donor
selection procedures. Apart from the prognostic appli-
cation, the large-scale miHA predictions also could
function as a powerful tool in selecting candidate
miHAs involved in the GVT effect and GVHD for
further evaluation in in vitro and in vivo experiments.ACKNOWLEDGMENTS
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